Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Collaborative Innovations in Childhood Cancer Therapies.
Valtingojer I, Lièvre S, Bordes P, Paranjpe K, Thompson W, Shah S, Fantin V, Jacquemet-Ross W, Adamson PC. Valtingojer I, et al. Handb Exp Pharmacol. 2024;286:33-50. doi: 10.1007/164_2024_725. Handb Exp Pharmacol. 2024. PMID: 39177748 Review.
Refined high-content imaging-based phenotypic drug screening in zebrafish xenografts.
Sturtzel C, Grissenberger S, Bozatzi P, Scheuringer E, Wenninger-Weinzierl A, Zajec Z, Dernovšek J, Pascoal S, Gehl V, Kutsch A, Granig A, Rifatbegovic F, Carre M, Lang A, Valtingojer I, Moll J, Lötsch D, Erhart F, Widhalm G, Surdez D, Delattre O, André N, Stampfl J, Tomašič T, Taschner-Mandl S, Distel M. Sturtzel C, et al. Among authors: valtingojer i. NPJ Precis Oncol. 2023 May 18;7(1):44. doi: 10.1038/s41698-023-00386-9. NPJ Precis Oncol. 2023. PMID: 37202469 Free PMC article. Review.
TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC.
Tammaccaro SL, Prigent P, Le Bail JC, Dos-Santos O, Dassencourt L, Eskandar M, Buzy A, Venier O, Guillemot JC, Veeranagouda Y, Didier M, Spanakis E, Kanno T, Cesaroni M, Mathieu S, Canard L, Casse A, Windenberger F, Calvet L, Noblet L, Sidhu S, Debussche L, Moll J, Valtingojer I. Tammaccaro SL, et al. Among authors: valtingojer i. Pharmaceuticals (Basel). 2023 Apr 6;16(4):553. doi: 10.3390/ph16040553. Pharmaceuticals (Basel). 2023. PMID: 37111311 Free PMC article.
YAP1 is essential for malignant mesothelioma tumor maintenance.
Calvet L, Dos-Santos O, Spanakis E, Jean-Baptiste V, Le Bail JC, Buzy A, Paul P, Henry C, Valence S, Dib C, Pollard J, Sidhu S, Moll J, Debussche L, Valtingojer I. Calvet L, et al. Among authors: valtingojer i. BMC Cancer. 2022 Jun 10;22(1):639. doi: 10.1186/s12885-022-09686-y. BMC Cancer. 2022. PMID: 35689194 Free PMC article.